4.1 Article

Next Generation Sequencing in the Clinic: a Patterns of Care Study in a Retrospective Cohort of Subjects Referred to a Genetic Medicine Clinic for Suspected Lynch Syndrome

Journal

JOURNAL OF GENETIC COUNSELING
Volume 25, Issue 3, Pages 515-519

Publisher

SPRINGER
DOI: 10.1007/s10897-015-9902-0

Keywords

Next generation sequencing; Gene panel; Lynch syndrome; Patterns of care; Colorectal cancer; ColoSeq

Funding

  1. Patient-Centered Outcomes Research Career Development Program from the Agency for Healthcare Research and Quality/University of Washington [K12 HS021686]
  2. National Human Genome Research Institute [U01 HG0006507, U01HG007307]

Ask authors/readers for more resources

Next generation sequencing (NGS) gene panels are increasingly used in medical genetics clinics for the evaluation of common inherited cancer syndromes, but the clinical efficacy of these tests, and the factors driving clinical providers to order them are unclear. We conducted a patterns-of-care study to compare patients evaluated with NGS gene panels with a reference group. We abstracted demographic, socioeconomic, and clinical information in a retrospective cohort of patients referred to a large medical genetics clinic for evaluation of inherited colorectal cancer and polyposis syndromes. Patients tested with NGS gene panels were more likely to be insured compared to the reference group (85.3 % vs. 69.2 %, p = 0.0068),less likely to have prior tumor tissue testing (29.4 % vs. 54.3 %, p = 0.0004), and less likely to have an abnormal tumor tissue test result (46.7 % vs. 74.5 %, p = 0.01). No significant differences were found between groups in age, gender, race, employment status, personal history of colorectal cancer, or proportion of patients fulfilling Lynch syndrome clinical criteria. Patients with NGS testing were less likely to have a pathogenic/likely pathogenic variant detected (13.7 % vs. 31.9 %, p = 0.002). Patients referred for NGS testing to evaluate inherited colorectal cancer/polyposis risk appear to undergo tumor tissue testing less frequently than non-NGS testing patients. Further studies are needed to assess the most effective and cost-effective approach to genomic diagnosis in this patient population.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Public, Environmental & Occupational Health

Relationship between genetic knowledge and familial communication of CRC risk and intent to communicate CRCP genetic information: insights from FamilyTalk eMERGE III

Sukh Makhnoon, Deborah J. Bowen, Brian H. Shirts, Stephanie M. Fullerton, Hendrika W. Meischke, Eric B. Larson, James D. Ralston, Kathleen Leppig, David R. Crosslin, David Veenstra, Gail P. Jarvik

Summary: This study found that patients' genetic knowledge was associated with their future intended familial communication of genetic information, but not with current communication of colorectal cancer risk. Better family functioning was associated with more frequent current communication of CRC risk.

TRANSLATIONAL BEHAVIORAL MEDICINE (2021)

Article Public, Environmental & Occupational Health

What improves the likelihood of people receiving genetic test results communicating to their families about genetic risk?

Deborah J. Bowen, Sukh Makhnoon, Brian H. Shirts, Stephanie M. Fullerton, Eric Larson, James D. Ralston, Kathleen Leppig, David R. Crosslin, David Veenstra, Gail P. Jarvik

Summary: The study found infrequent communication of cancer risk among family members, with a low overall impact of communication within the family. Age and education were associated with the frequency of familial communication, but not with the cancer-related impact of familial communication.

PATIENT EDUCATION AND COUNSELING (2021)

Article Genetics & Heredity

One in seven pathogenic variants can be challenging to detect by NGS: an analysis of 450,000 patients with implications for clinical sensitivity and genetic test implementation

Stephen E. Lincoln, Tina Hambuch, Justin M. Zook, Sara L. Bristow, Kathryn Hatchell, Rebecca Truty, Michael Kennemer, Brian H. Shirts, Andrew Fellowes, Shimul Chowdhury, Eric W. Klee, Shazia Mahamdallie, Megan H. Cleveland, Peter M. Vallone, Yan Ding, Sheila Seal, Wasanthi DeSilva, Farol L. Tomson, Catherine Huang, Russell K. Garlick, Nazneen Rahman, Marc Salit, Stephen F. Kingsmore, Matthew J. Ferber, Swaroop Aradhya, Robert L. Nussbaum

Summary: The study evaluated the impact of technically challenging variants on clinical genetic tests, finding considerable variability in the analytic and clinical sensitivity of NGS workflows. Some challenging variants were not detected by all workflows, highlighting the importance of test design, validation, and selection for clinicians.

GENETICS IN MEDICINE (2021)

Article Allergy

Molecular diagnosis of childhood immune dysregulation, polyendocrinopathy, and enteropathy, and implications for clinical management

Sarah K. Baxter, Tom Walsh, Silvia Casadei, Mary M. Eckert, Eric J. Allenspach, David Hagin, Gesmar Segundo, Ming K. Lee, Suleyman Gulsuner, Brian H. Shirts, Kathleen E. Sullivan, Michael D. Keller, Troy R. Torgerson, Mary-Claire King

Summary: This study identified damaging germline mutations in 27 genes in about 39% of patients with childhood-onset immune dysregulation, polyendocrinopathy, and enteropathy. Many of these genes had not been previously associated with the disease. Genetic diagnoses of these patients have clinical implications and can potentially alter therapeutic management, providing targeted treatments and recommendations for hematopoietic cell transplantation.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Article Medical Informatics

Infobuttons for Genomic Medicine: Requirements and Barriers

Luke V. Rasmussen, John J. Connolly, Guilherme Del Fiol, Robert R. Freimuth, Douglas B. Pet, Josh F. Peterson, Brian H. Shirts, Justin B. Starren, Marc S. Williams, Nephi Walton, Casey Overby Taylor

Summary: This study aimed to understand potential barriers to the adoption of health information technology projects released as free and open source software. Through a survey and analysis of research consortia participants, 14 categories of perceived barriers were identified, with recommendations for addressing them. FOSS developers need to ensure their systems are easy to trial and implement, and institutional champions will remain critical for prioritizing genomic medicine projects.

APPLIED CLINICAL INFORMATICS (2021)

Article Genetics & Heredity

Multiplexing mutation rate assessment: determining pathogenicity of Msh2 variants in Saccharomyces cerevisiae

Anja R. Ollodart, Chiann-Ling C. Yeh, Aaron W. Miller, Brian H. Shirts, Adam S. Gordon, Maitreya J. Dunham

Summary: This study established a new method to simultaneously determine the mutation rate of multiple strains using continuous culture devices and deep sequencing, successfully applied to assay the mutation rate of Saccharomyces cerevisiae strains with mutations in the Msh2 gene. The method was proven to be accurate and reliable, and it can be applied to studying the mutation rate of various microbial species.

GENETICS (2021)

Article Genetics & Heredity

Closing the gap: Systematic integration of multiplexed functional data resolves variants of uncertain significance in BRCA1, TPS3, and PTEN

Shawn Fayer, Carrie Horton, Jennifer N. Dines, Alan F. Rubin, Marcy E. Richardson, Kelly McGoldrick, Felicia Hernandez, Tina Pesaran, Rachid Karam, Brian H. Shirts, Douglas M. Fowler, Lea M. Starita

Summary: The combination of multiplexed functional data with clinical data can effectively drive the reclassification of missense variants, reducing the number of variants of uncertain significance and having a major impact on clinical variant interpretation.

AMERICAN JOURNAL OF HUMAN GENETICS (2021)

Article Urology & Nephrology

Inherited TP53 Variants and Risk of Prostate Cancer

Kara N. Maxwell, Heather H. Cheng, Jacquelyn Powers, Roman Gulati, Elisa M. Ledet, Casey Morrison, Anh Le, Ryan Hausler, Jill Stopfer, Sophie Hyman, Wendy Kohlmann, Anne Naumer, Jennie Vagher, Samantha E. Greenberg, Lorraine Naylor, Mercy Laurino, Eric Q. Konnick, Brian H. Shirts, Saud H. AlDubayan, Eliezer M. Van Allen, Bastien Nguyen, Joseph Vijai, Wassim Abida, Maria Carlo, Marianne Dubard-Gault, Daniel J. Lee, Luke D. Maese, Diana Mandelker, Bruce Montgomery, Michael J. Morris, Piper Nicolosi, Robert L. Nussbaum, Lauren E. Schwartz, Zsofia Stadler, Judy E. Garber, Kenneth Offit, Joshua D. Schiffman, Peter S. Nelson, Oliver Sartor, Michael F. Walsh, Colin C. Pritchard

Summary: Complementary analysis of prostate cancer incidence in LFS males and gTP53 prevalence in prostate cancer cohorts suggests that gTP53 predisposes to aggressive prostate cancer. Prostate cancer should be considered as part of LFS screening protocols and TP53 should be considered in germline prostate cancer susceptibility testing.

EUROPEAN UROLOGY (2022)

Article Genetics & Heredity

Harmonizing variant classification for return of results in the All of Us Research Program

Steven M. Harrison, Christina A. Austin-Tse, Serra Kim, Matthew Lebo, Annette Leon, David Murdock, Aparna Radhakrishnan, Brian H. Shirts, Marcie Steeves, Eric Venner, Richard A. Gibbs, Gail P. Jarvik, Heidi L. Rehm

Summary: The All of Us Research Program aims to accelerate research and improve healthcare by collecting data from one million people in the United States. Participants can choose to receive genome analysis results, including actionable findings for certain gene-disorder pairs. Four participating clinical laboratories conducted a prelaunch study to ensure consistent reporting of variant classifications, with 99.1% concordance and resolution of all reportability differences through reassessment and discussion. This approach will be maintained for continuous classification harmonization and consistent reporting within the program.

HUMAN MUTATION (2022)

Article Genetics & Heredity

Laboratory-related outcomes from integrating an accessible delivery model for hereditary cancer risk assessment and genetic testing in populations with barriers to access

Laura M. Amendola, Elizabeth Shuster, Michael C. Leo, Michael O. Dorschner, Bradley A. Rolf, Brian H. Shirts, Marian J. Gilmore, Sonia Okuyama, Jamilyn M. Zepp, Tia L. Kauffman, Kathleen F. Mittendorf, Cecilia Bellcross, Charisma L. Jenkins, Galen Joseph, Leslie Riddle, Sapna Syngal, Chinedu Ukaegbu, Katrina A. B. Goddard, Benjamin S. Wilfond, Gail P. Jarvik

Summary: This study aims to evaluate the laboratory-related outcomes of participants offered genomic testing based on cancer family history risk assessment tools. The study found that 5% of participants had a pathogenic/likely pathogenic cancer risk variant and 1% had a secondary finding. Participant personal history and PREMM5 score were associated with the category of findings.

GENETICS IN MEDICINE (2022)

Article Genetics & Heredity

An algorithm for optimal testing in co-segregation analysis

Ronald W. Buie, John Michael O. Ranola, Annie T. Chen, Brian H. Shirts

Summary: This paper proposes an algorithm to evaluate the variant information gain in familial cosegregation analysis, and validates its performance by comparing actual recruitment strategies with optimized testing strategies. The results show that the testing strategy indicated by the algorithm can achieve maximal information gain more rapidly.

HUMAN MUTATION (2022)

Article Genetics & Heredity

Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis

Shangqing Jiang, Patrick C. Mathias, Nathaniel Hendrix, Brian H. Shirts, Peter Tarczy-Hornoch, David Veenstra, Daniel Malone, Beth Devine

Summary: A cost-effectiveness model was constructed to evaluate the clinical and economic value of a CDS alert program providing PGx testing results in ACS and AF. The program was found to significantly reduce major clinical events and deaths in ACS and AF, and was cost-effective with an incremental cost-effectiveness ratio of $39,477/QALY compared to no alert program, under a willingness-to-pay threshold of $100,000/QALY gained.

PHARMACOGENOMICS JOURNAL (2022)

Article Health Care Sciences & Services

Socioeconomic Status and Interest in Genetic Testing in a US-Based Sample

E. J. Dusic, Deborah J. Bowen, Robin Bennett, Kevin C. Cain, Tesla Theoryn, Mariebeth Velasquez, Elizabeth Swisher, Jeannine M. Brant, Brian Shirts, Catharine Wang

Summary: This study found that socioeconomic status affects individuals' interest in pursuing hereditary cancer genetic testing, with factors such as education and household income being related to the level of interest.

HEALTHCARE (2022)

Article Medicine, Research & Experimental

The utility of cerebrospinal fluid-derived cell-free DNA in molecular diagnostics for the PIK3CA-related megalencephaly-capillary malformation (MCAP) syndrome: a case report

Wei-Liang Chen, Emily Pao, James Owens, Ian Glass, Colin Pritchard, Brain H. Shirts, Christina Lockwood, Ghayda M. Mirzaa

Summary: The megalencephaly-capillary malformation (MCAP) syndrome is an overgrowth disorder caused by mosaic gain-of-function variants in PIK3CA. This study reports the utility of cerebrospinal fluid (CSF)-derived cfDNA for the molecular diagnosis of MCAP syndrome and highlights the importance of minimally invasive approaches using cfDNA for accurate diagnosis and potential therapeutic implications for individuals with refractory epilepsy.

COLD SPRING HARBOR MOLECULAR CASE STUDIES (2022)

Article Oncology

Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative

Rachel Pearlman, Wendy L. Frankel, Benjamin J. Swanson, Dan Jones, Weiqiang Zhao, Ahmet Yilmaz, Kristin Miller, Jason Bacher, Christopher Bigley, Lori Nelsen, Paul J. Goodfellow, Richard M. Goldberg, Electra Paskett, Peter G. Shields, Jo L. Freudenheim, Peter P. Stanich, Ilene Lattimer, Mark Arnold, Thomas W. Prior, Mitchell Haut, Matthew F. Kalady, Brandie Heald, Ian Paquette, David J. Draper, Joanna M. Brell, Sameer Mahesh, Kisa Weeman, Shyamal Bastola, Jeffrey Zangmeister, Aruna Gowda, Filix Kencana, Albert Malcolm, Yinong Liu, Sharon Cole, Charles Bane, Chaoyang Li, Esther Rehmus, Colin C. Pritchard, Brian H. Shirts, Angela Jacobson, Shelly A. Cummings, Albert de la Chapelle, Heather Hampel

Summary: The study found that 7.1% of individuals with CRC have PGVs, and UTS alone is insufficient for identifying a large proportion of CRC patients with hereditary syndromes, including some with LS. Pan-cancer MGPT for all patients with CRC may be a better screening method.

JCO PRECISION ONCOLOGY (2021)

No Data Available